Arca
Skip to content
Tools
Tools

ROCK1, ROCK2: Rho-associated protein kinase

Family in Homo sapiens that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 2
  • In phases 1 to 3: 8
  • Sponsors: 8

Who is on it, and how far along

Every drug ChEMBL records acting on ROCK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8
  • Other 2

Approved2

  • Belumosudil
  • Netarsudil

Phase 33

  • Fasudil
  • Ripasudil
  • AMA0076

Phase 23

  • DE-104
  • SAR-407899 free base
  • Verosudil

Phase 12

  • AT-13148
  • Y-39983

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Amakem, NV110%
  • Kowa Research Institute, Inc.110%
  • Sanofi-Aventis110%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Rho-associated protein kinase inhibitor.
BelumosudilApprovedSanofi-AventisSmall moleculeInhibitor19
NetarsudilApprovedAlconSmall moleculeInhibitor12
FasudilPhase 3Woolsey PharmaceuticalsSmall moleculeInhibitor5
RipasudilPhase 3Kowa Research Institute, Inc.Small moleculeInhibitor5
AMA0076Phase 3Amakem, NVOtherInhibitor0
DE-104Phase 2Santen PharmaceuticalOtherInhibitor0
SAR-407899 free basePhase 2SanofiSmall moleculeInhibitor0
VerosudilPhase 2Aerie PharmaceuticalsSmall moleculeInhibitor0
AT-13148Phase 1—Small moleculeInhibitor0
Y-39983Phase 1—Small moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov.
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma PatientsNetarsudilPhase 4RecruitingBrett KingSep 29, 2026
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHDBelumosudilNot applicableRecruitingFirst Affiliated Hospital of Zhejiang UniversityAug 31, 2026
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseBelumosudilPhase 3RecruitingSanofiAug 18, 2026
Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsBelumosudilPhase 1Not yet recruitingSanofiJul 24, 2026
Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)BelumosudilPhase 2Not yet recruitingDennis KimJun 11, 2026
A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCTBelumosudilPhase 2RecruitingWeiShiMay 26, 2026
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular HypertensionNetarsudilPhase 4RecruitingIndiana UniversityMay 14, 2026
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHDBelumosudilPhase 1Not yet recruitingStanford UniversityMar 19, 2026
Rocklatan vs Latanoprost Post-DSLTNetarsudilPhase 4RecruitingEye Centers of Southeast TexasMar 12, 2026
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension PatientsNetarsudilPhase 4RecruitingMayo ClinicJan 8, 2026
A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate CancerFasudilPhase 2Recruitingbaotai LiangNov 26, 2025
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat GlaucomaNetarsudilPhase 4RecruitingInsight Eyecare Specialties, Inc. dba Vision Source Eyecare,Oct 7, 2025
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)BelumosudilPhase 4Not yet recruitingSanofiAug 22, 2025
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHDBelumosudilPhase 1RecruitingM.D. Anderson Cancer CenterAug 17, 2025
Retinal Ganglion Cell Neuroprotection Under Prostaglandin AnaloguesNetarsudil—Not yet recruitingAssociation for Innovation and Biomedical Research on Light and ImageJul 20, 2025
Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)NetarsudilPhase 4Not yet recruitingCenter for Sight Las VegasJul 3, 2025
The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal DystrophyNetarsudil—Enrolling by invitationUniversity Hospital DubravaMay 14, 2025
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian CancerFasudilPhase 2RecruitingZhejiang Provincial People's HospitalMar 24, 2025
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate CancerFasudilPhase 2 / Phase 3Recruitingbaotai LiangMar 6, 2025
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)FasudilPhase 2RecruitingHelse Stavanger HFApr 12, 2024
The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract SurgeryRipasudilPhase 3RecruitingSingapore Eye Research InstituteSep 21, 2023
Study to Assess Safety and Tolerability of Multiple Doses of EO2002RipasudilPhase 1RecruitingAsociación para Evitar la Ceguera en MéxicoDec 5, 2022
Descemet Endothelial Thickness Comparison Trial IRipasudilPhase 3Active, not recruitingStanford UniversityMar 21, 2022
Descemet Endothelial Thickness Comparison Trial IIRipasudilPhase 3Active, not recruitingStanford UniversityMar 11, 2022
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)FasudilPhase 2Active, not recruitingWoolsey PharmaceuticalsFeb 1, 2022
Glanatec(R) for Descemet Stripping in Fuch's Endothelial DystrophyRipasudilPhase 4RecruitingMarian Macsai, MDAug 15, 2017

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111459, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.